1800 244 735

Research articles

Click on this link to read our latest research articles.

Click on this link to find out more about Huntington’s NSW ACT Research grant opportunities.

HD Buzz

HDBuzz is a collaboration of scientists who write Huntington’s disease research news in plain language for the global HD community. They have allowed us to retrieve their articles for the NSW ACT Huntington’s community.

Westmead HD Outreach Service

The Outreach Service is part of a multidisciplinary team of medical, nursing and allied health services which provides review, intervention, treatment, case management, counselling, support, education and management of problems and issues associated with Huntington’s for patients, their families and carers. In addition to this care, the service has been involved in local and major international research studies since its establishment at Westmead Hospital in 1995. Hundreds of volunteers have generously participated in research to better understand the disease and in the search for effective treatments.

Westmead Hospital is a HSG Credential Research Site. Professor Clement Loy is the Principal Investigator for this site.

Global research collaboration

The Huntington Study Group (HSG) is the world’s first HD cooperative therapeutic research organization. Today, HSG is a world leader in facilitating high quality clinical research trials and studies that bring us closer to finding more effective treatments for HD and reducing the burden of HD for families affected by the disease.

HSG is an organization of compassionate professionals dedicated to finding treatments that make a difference, providing rigorous care initiatives, and improving the quality of life and outcomes for HD families. They bring together families, medical professionals, clinical researchers, HD advocacy groups, and sponsors to raise awareness of HD, share knowledge and best practices, and develop innovative treatments.

Enroll-HD

Enroll-HD is a clinical research platform and the world’s largest observational study for Huntington’s disease families. It is a resource for the entire HD community, including families, clinicians, researchers, advocates, and anyone else who has a connection to or an interest in HD.

Huntington’s Disease Network of Australia

The Huntington’s Disease Network of Australia (HDNA) is a project conceived by Professor Julie Stout of Monash University. Formed in 2020 to coordinate efforts that enhance care and services for HD and prepare for the advent of new HD treatments. The Map-HD Registry is for people in Australia who are affected by HD. All family members or people affected by HD are encouraged to register, whether or not they are at risk themselves.
 
 

          Huntington's Disease Network of Australia

What does COVID-19 mean for Huntington’s disease families and HD research?

Published date: 6 April, 2020

COVID-19, short for coronavirus disease 2019, has taken the world by storm in almost every sense – many people have been infected with the SARS-CoV-2 virus, it’s created shopping pandemonium in stores, and many people are isolated at home. But behind that frenzied storm, scientists around the world have been working tirelessly to move research ... Read more

New molecule can reverse the Huntington's disease mutation in lab models

Published date: 6 April, 2020

A collaborative team of scientists from Canada and Japan have identified a small molecule which can change the CAG-repeat length in different lab models of Huntington’s disease. CAG repeats are unstable Huntington’s disease is caused by a stretch of C, A and G chemical letters in the Huntingtin gene, which are repeated over and over ... Read more

Huntington’s disease therapeutics conference 2020 – Day 1

Published date: 12 March, 2020

Our new writers Rachel Harding and Sarah Hernandez report from the Huntington’s Disease Therapeutics Conference – the biggest annual gathering of HD researchers.

THE LATEST HD SCIENCE

Published date: 4 March, 2020

Change to the design of Roche’s ongoing huntingtin lowering trial – known as the GENERATION HD1 study The pharmaceutical giant Roche ran an earlier, smaller, study with antisense oligonucleotides or ASOs as potential HD treatments. That was a safety study – designed to determine whether or not giving ASOs via the spinal fluid led to ... Read more

Huntington’s disease therapeutics conference 2020 – Day 3

Published date: 3 March, 2020

Rachel and Sarah report from the Huntington’s Disease Therapeutics Conference – the biggest annual gathering of HD researchers. Be sure to catch up on Day 1 and Day 2. Thursday morning – Huntingtin lowering Good morning everyone! We are back for Day 3 at the CHDI meeting in Palm Springs which is all about huntingtin ... Read more

Huntington’s disease therapeutics conference 2020 – Day 2

Published date: 1 March, 2020

Rachel and Sarah report from the Huntington’s Disease Therapeutics Conference – the biggest annual gathering of HD researchers. Be sure to catch up on Day 1! Good morning everyone! We are back for day 2 of the CHDI therapeutics conference in Palm Springs. Lots of exciting talks coming up! Wednesday morning – The path to ... Read more

Screening the entire genome for new drug targets for HD

Published date: 23 February, 2020

A recently published study in the journal ‘Neuron’ has identified new potential therapeutic targets for the treatment of Huntington’s disease (HD). The work conducted by Professor Myriam Heiman and colleagues used cutting-edge genetic technologies and discovered several genes could modify HD progression in their models in the lab. Many of these genes have not been ... Read more

The third dimension: using minibrains to understand brain development changes in HD

Published date: 6 February, 2020

A new publication used tiny 3D brain models created from human cells to show that the mutation that causes HD could lead to early changes in brain development. However, it’s clear that HD patients can, and do, develop fully mature brain cells that maintain normal function, in most cases, for decades. So let’s put these ... Read more

Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement

Published date: 3 January, 2020

DNA-based drugs called antisense oligonucleotides, or ASOs, are now in multiple clinical trials in Huntington’s disease, aiming to lower production of the harmful mutant huntingtin protein in the brain. Wave Life Sciences has been running parallel trials of two new ASO drugs, administered by injection into the spine. Just before the new year, Wave announced ... Read more

Huntington’s Disease research update

Published date: 12 November, 2019

Handwriting Can Help Identify Asymptomatic Huntington’s, Study Suggests.